γδT cells and the future of drug resistant immunotherapyPublished: July 4, 2019
Cellular Immuno-Oncology 4.0
Lawrence Lamb As Executive Vice President and Chief Scientific Officer, Dr Lamb currently directs clinical and translational research strategy and operations for Incysus Therapeutics. Dr Lamb was first to describe the association between relapse-free survival and γδT cell recovery in bone marrow transplant patients. For 26 years, most recently as Professor of Medicine and Director of the Cell Therapy Laboratory at the University of Alabama at Birmingham, Dr Lamb developed the scientific support for γδT cell-based immunotherapies. Today, this work has resulted in FDA approval for both the first clinical trials for allogeneic γδT cell therapy in leukemia patients undergoing haploidentical stem cell transplants and the first gene-modified γδT cell therapy for high-grade gliomas.DOI: 10.18609/cgti.2019.067
Citation: Cell & Gene Therapy Insights 2019; 5(5), 577-583.